Bavarian Nordic A/S (BVNRY) Research

Bavarian Nordic A/S is a Danish biopharmaceutical company specializing in the development, production, and global commercialization of essential, life-saving vaccines. Its marketed portfolio includes non-replicating vaccines for smallpox and monkeypox (known as IMVAMUNE, IMVANEX, and JYNNEOS), as well as human rabies protection (Rabipur/RabAvert), a tick-borne encephalitis vaccine (Encepur), and an Ebola vaccine (MVABEA). The company also boasts a robust pipeline of investigational therapies. Notably, MVA-BN (freeze-dried) has concluded Phase III trials for smallpox, and MVA-BN RSV is currently in Phase III clinical development for respiratory syncytial virus (RSV). Additionally, ABNCoV2, a candidate for SARS-CoV-2, successfully completed its Phase II clinical trial, and TAEK-VAC is advancing through Phase I/II studies for select advanced HER2 and brachyury-expressing cancers. Bavarian Nordic maintains strategic alliances, including a licensing and collaboration agreement with AdaptVac, alongside further licensing arrangements with the National Cancer Institute and the Public Health Service. Its commercial operations and presence span numerous countries, such as the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, and Japan, reflecting a broad international footprint. Established in 1992, Bavarian Nordic A/S is headquartered in Hellerup, Denmark.

Open Bavarian Nordic A/S (BVNRY) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.